{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:11:38Z","timestamp":1781010698072,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1124\/dmd.118.084897","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T19:35:13Z","timestamp":1544643313000},"page":"340-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans"],"prefix":"10.1016","volume":"47","author":[{"given":"Makiko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Takakusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.084897_bib1","unstructured":"Aoki K, Tsuruoka H, Hayashi N, Yoshida J, and Asoh Y (2008) inventors, Daiichi Sankyo Co. Ltd., assignee. Atropisomer of pyrrole derivative. WO2008126831A1. 2008 Oct 23."},{"key":"10.1124\/dmd.118.084897_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.118.084897_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","article-title":"CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats","volume":"358","author":"Arai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.084897_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.118.084897_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/dmd.118.084897_bib6","unstructured":"Canne Bannen L, Chen J, Dalrymple LE, Flatt BT, Forsyth TP, Gu XH, Mac MB, Mann LW, Mann G, Martin R, et al. (2006) inventors, Exelixis, Inc., assignee. Pyrrole derivatives as pharmaceutical agents. WO2006012642A2. 2006 Feb 2."},{"key":"10.1124\/dmd.118.084897_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00498250310001649341","article-title":"Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data","volume":"34","author":"Cook","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.084897_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/dmd.118.084897_bib9","series-title":"Guidance for Industry: Safety Testing of Drug Metabolites","year":"2016"},{"key":"10.1124\/dmd.118.084897_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0960-0760(95)00021-Q","article-title":"Mineralocorticoid receptors and hypertension","volume":"53","author":"Funder","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.118.084897_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/dmd.110.037184","article-title":"Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin K inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway","volume":"39","author":"Kassahun","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084897_bib12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.084897_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/1087057107308892","article-title":"Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2\/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans","volume":"12","author":"Li","year":"2007","journal-title":"J Biomol Screen"},{"key":"10.1124\/dmd.118.084897_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 \u03b2-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lomb\u00e8s","year":"1995","journal-title":"Circulation"},{"key":"10.1124\/dmd.118.084897_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084897_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084897_bib16","doi-asserted-by":"crossref","first-page":"F1065","DOI":"10.1152\/ajprenal.00147.2007","article-title":"Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress","volume":"293","author":"Patni","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/dmd.118.084897_bib17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.084897_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.084897_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","article-title":"In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates","volume":"34","author":"Rautio","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084897_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1124\/dmd.118.084897_bib21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1124\/dmd.118.084897_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1124\/dmd.118.084897_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084897_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","article-title":"Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats","volume":"93","author":"Siragy","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1124\/dmd.118.084897_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1124\/dmd.118.084897_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.1.4.595","article-title":"Breast cancer resistance protein in pharmacokinetics and drug-drug interactions","volume":"1","author":"Xia","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.118.084897_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","article-title":"Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys","volume":"47","author":"Yamada","year":"2017","journal-title":"Xenobiotica"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.084897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:25:06Z","timestamp":1739957106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0090955624078607"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.084897","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.084897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}